INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger...
Transcript of INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger...
![Page 1: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/1.jpg)
I N T R O D U C T I O N T O H I V
P A T H O P H Y S I O L O G Y
R O G E R PA R E D E SM D, P H D
I N F E C T I O U S D I S E A S E S S E R V I C E & I R S I C A I X A A I D S R E S E A R C H I N S T I T U T EH O S P I T A L U N I V E R S I T A R I G E R M A N S T R I A S I P U J O L
B A D A L O N A , C A T A L O N I A , S P A I N
![Page 2: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/2.jpg)
DISCLOSURES
• I have received research grants from MSD, ViiV and Gilead
• I have participated in advisory boards for MSD and ViiV
• I don’t have stock options
![Page 3: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/3.jpg)
![Page 4: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/4.jpg)
![Page 5: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/5.jpg)
Días
![Page 6: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/6.jpg)
![Page 7: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/7.jpg)
HIV LIFE CYCLE AND ART
![Page 8: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/8.jpg)
VIRAL LOAD FOLLOWING TREATMENT INTERRUPTION
Ananworanich J. CROI 2017, Seattle, WA. #124.
Median time to viral rebound: 26 days (range 13-48)Highest VL at rebound (median): 5169 (2005 – 13462)
• N=8• ART started at Fiebig I (HIV RNA+, p24 Ag-, Ab-) for ≥ 96 w.• VL <50 c/mL ≥48 w & CD4 >400 cells.• Resume ART if two VL >1000 c/ml ortwo CD4 <350 cells.• TI for 24 w. VL every 3-7 days.
Hypothesis.• At least 30% of individuals will havedelayed time to VL rebound (VL<50 at 24 w).• Proceed to stage 2 if ≥ 1 person has VL <50 c/ml at week 12.
![Page 9: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/9.jpg)
HIV is the greatest escapist
![Page 10: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/10.jpg)
NK
B
CD8
CD4 Adaptive immunity
Innate immunity
HIV-1 Strategies to counteract host immunity
TRIM
TETHERIN
Intrinsic immunity
CypA
Vif
Vpx
![Page 11: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/11.jpg)
Population level Individual level
HUGE GENETIC DIVERSITY
Sanger sequencing
Deep sequencing
![Page 12: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/12.jpg)
1. High replication rate: 109-12 new virions/day
2. Error-prone polymerase:
- 1 mutation / 10,000 bp
- 3-8 recombination events / mutation event
3. Cellular mechanisms: MDR1 gene codes for P-
glycoprotein
4. Role of RNAseH
5. Selective pressure of Abs & CTLs against HIV epitopes
6. Viral pool size and availability of target cells
• Balance between mutation rate, drift and selection
![Page 13: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/13.jpg)
QUASISPECIES
“A population of viruses that share a common origin but which have distinct genomic sequences as a result from mutation, drift and the impact of selection”
![Page 14: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/14.jpg)
In ARV-naïve subjects chronically infected with a “wild-type” HIV-1
• All non-deletereous single mutants likely preexist
• Few double mutants preexist
• Almost no triple mutants are expected
![Page 15: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/15.jpg)
![Page 16: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/16.jpg)
![Page 17: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/17.jpg)
![Page 18: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/18.jpg)
![Page 19: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/19.jpg)
![Page 20: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/20.jpg)
Pressure 1
![Page 21: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/21.jpg)
Pressure 2
Pressure 1
![Page 22: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/22.jpg)
Stop pressure
Pressure 2
Pressure 1
![Page 23: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/23.jpg)
Stop pressure
![Page 24: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/24.jpg)
Mutation rate
Drift Selection
DIVERSITY
![Page 25: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/25.jpg)
Drift
![Page 26: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/26.jpg)
Pereyra et al, Science 2010
Kiepiela et al, Nature 2004
HLA-I molecules are a major driving force of HIV-1 evolution
![Page 27: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/27.jpg)
KA
F SP
EV I
P
HLA-I
P2 P9
N
K PE
V I PG
SF
CD8+ T-cell responses and HIV-1 escape
![Page 28: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/28.jpg)
HLA class I alleles are also highly diverse
![Page 29: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/29.jpg)
Host HLA genetics and HIV diversity: frequent transmission of escaped epitopes and epitope loss over time
![Page 30: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/30.jpg)
![Page 31: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/31.jpg)
GP160 FROM THE OUTSIDE
![Page 32: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/32.jpg)
RESTRICTION FACTORS
![Page 33: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/33.jpg)
CD8Co
pies
Vira
l RN
A/m
l
CD4+ T cells/ml
HOST RACE HIV EVOLUTION
WT
R2
E1
R3
E2
R4
E3 E4
R1
![Page 34: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/34.jpg)
Metzner K, Paredes R, CHAIN Training slides
QUASISPECIES AS A SURVIVAL STRATEGY
![Page 35: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/35.jpg)
Brenchley J M et al. J Exp Med 2004;200:749-759
HIV INFECTION DAMAGES THE GALT
% CD4+ T-cells
![Page 36: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/36.jpg)
MICROBIAL TRANSLOCATION IN HIV
![Page 37: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/37.jpg)
MICROBIAL TRANSLOCATION IN HIV PATHOGENESIS
Marchetti et al. Clin Microbiol Rev. 2013
![Page 38: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/38.jpg)
Bacterial translocation and clinical progression
Marchetti G, et al. AIDS 2011;25(11):1385-94.
ICONA Cohort
- Documented last HIV-negative test and first HIV-positive
- Plasma sample stored while ART-naive
N=379.
Circulating LPS in the first year of infection is a good predictor of progression
![Page 39: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/39.jpg)
INFLAMMAEGING
![Page 40: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/40.jpg)
MICROBIOME IN HIV
Guillén et al. Mucosal Immunology 2018
![Page 41: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/41.jpg)
DYSBIOSIS BY GENE RICHNESS
Guillén et al. Mucosal Immunology 2018
![Page 42: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/42.jpg)
LOW MICROBIAL GENE RICHNESS LINKED TO NADIR CD4
Guillén et al. Mucosal Immunology 2018
![Page 43: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/43.jpg)
MICROBIOME IN HIV
Guillén et al. Mucosal Immunology 2018
![Page 44: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/44.jpg)
MICROBIOME IN HIV
Guillén et al. Mucosal Immunology 2018
![Page 45: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/45.jpg)
VAGINAL DYSBIOSIS RECOGNIZABLE AS COMMUNITY-TYPES
![Page 46: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/46.jpg)
CAPRISA-004
![Page 47: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/47.jpg)
CAPRISA-004
![Page 48: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/48.jpg)
TDF DEPLETED BY GARDENERELLA BUT NOT LACTOBACILLUS
![Page 49: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/49.jpg)
TDF METABOLISED TO ADENINE
![Page 50: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/50.jpg)
MULTIPLE BV BACTERIA (BUT NOT L ACTOBACILLUS) CAN METABOLIZE TENOFOVIR
![Page 51: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/51.jpg)
Maier Nature 2018
EXTENSIVE IMPACT OF NON-ANTIBIOTIC DRUGS ON HUMAN GUT BACTERIA
![Page 52: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/52.jpg)
MICROBIOME IN CANCER
Gopalakrishnan et al, Cancer Cell 2018
![Page 53: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/53.jpg)
X4 (SI) R5 (NSI)
CXCR4 CCR5CD4
T-cell lines Primary lymphocytes Monocyte/macrophages
CD4 Naïve CD4 memory
Dual tropic
TROPISM PREDICTION
![Page 54: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/54.jpg)
Koot M, et al: Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS. Annals Int Med 1993
TROPISM
![Page 55: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/55.jpg)
RATE OF PROGRESSION TO CD4+<350, INITIATION OF ART OR DEATH
Goetz. JAIDS 2009
![Page 56: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/56.jpg)
TIME OF X4 VIRUS EMERGENCE IN RELATION TO CD4 INFLECTION POINT
Shepherd. MACS cohort, JID 2008
![Page 57: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/57.jpg)
TROPISM & CD4 LOSS BEFORE ART
Waters CID 2008
![Page 58: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/58.jpg)
TROPISM & CD4 GAIN AFTER ART
Waters CID 2008
![Page 59: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/59.jpg)
WHY DO WE NEED TO CURE HIV? Life expectancy remains reduced on cART
Ongoing morbidity on cART
Prevent HIV transmission
Substantial stigma and discrimination
Lifelong cART: adherence toxicity long term-cost
J.Martinez-Picado
Lohse, Ann Int Med 2007; Hogg. Lancet 2008; Deeks & Phillips, BMJ 2009; May, BMJ 2011
Estimated 2015 AIDS investment for universal prevention, treatment, care and
support
22 billion USD
![Page 60: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/60.jpg)
BARRIERS TO CURE HIV INFECTION
J.Martinez-Picado
Where is the virus and how is it maintained in the face of suppressive therapy?
Residual replication
Latent infection
inflammationimmune activation
![Page 61: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/61.jpg)
HIV CURE: 2-MODELS
J.Martinez-Picado
![Page 62: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/62.jpg)
J.Martinez-Picado
STRATEGIES TO CURE HIVTreatmentoptimization& intensification
(eliminateall replication)
Reversal of HIV latency
(increase viral production)
Immune-basedtherapies
(reverse pro-latency signaling)
Therapeuticvaccination
(to enhance host-control)
Genetherapy
![Page 63: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/63.jpg)
ICISTEM CONSORTIUM
International collaboration to guide and investigate the potential for HIV cure in HIV-infected patients requiring allogeneic stem cell transplantation for hematological disorders
AIM 1To guide clinicians involved inallogeneic SCT procedures in HIVinfected individuals
AIM 2To better understand the underlyingbiological processes leading to viralreservoir reduction and potentialcases of HIV-1eradication/remission.
www.icistem.org
Principal Investigators:Javier Martinez PicadoAnnemarie Wensing
Current Status40 individuals transplanted. ATI in 2who received CCR5Δ32 cells (sep2017 and nov 2018) without viralrebound. ATI with intervention for 5individuals transplanted withwildtype cells is being prepared
![Page 64: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/64.jpg)
CONCLUSIONS• HIV is the great scapist
–Diversity• HIV• HLA
– Integrated DNA–Env glycosylation–GALT damage– Inflammaging
![Page 65: INTRODUCTION TO HIV PATHOPHYSIOLOGY · 2021. 9. 3. · introduction to hiv pathophysiology roger paredes. md, phd. infectious diseases service & irsicaixa aids research institute.](https://reader036.fdocuments.in/reader036/viewer/2022071611/614a763612c9616cbc696e52/html5/thumbnails/65.jpg)
Thanks for the slides to : Christian Brander
Javier Martínez PicadoMiguel Ángel Martínez
Júlia Garcia-PradoEster Ballana
Josep Maria Llibre